|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, despite low arterial lactate, patients with a high APACHEⅡ score, high C-reactive protein levels, and chronic heart failure had a poorer prognosis.
|
28923305 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficient electron-mediated electrochemical biosensor of gold wire for the rapid detection of C-reactive protein: A predictive strategy for heart failure.
|
31400725 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other predictors included ischemic etiology (HR 1.33, p=0.023), prior hospitalization for heart failure (HR 1.34, p=0.017), C-reactive protein (HR 1.04, p<0.001), and statin use (HR 0.70, p=0.016).
|
29169753 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results hint towards an association of less common CRP genetic variants with increased mortality risk, depressive symptoms and peripheral CRP levels in this population of HF patients thereby suggesting a possible role of the inflammatory system as link between poor prognosis in HF and depressive symptoms.
|
29627531 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The patient finally had a partial clinical response (reduction in fever and irritability) and complete laboratory response (improved C-reactive protein and serum amyloid A levels) to humanized anti-IL-6 receptor antibody (MRA), but died from congestive heart failure and interstitial pneumonia 2 months after initiation of therapy.
|
16802372 |
2006 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Female gender, history of heart failure or left ventricular ejection fraction <40%, and high levels (>1 mg/dL) of C-reactive protein (CRP) were independently associated with left atrial SEC/thrombosis.
|
27730663 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
To describe correlations and agreement between salivary and serum B-type natriuretic peptide (BNP), C-reactive protein (CRP), interleukin (IL)-6, and IL-10 and determine which biomarkers predict worse functional class in patients with heart failure (HF).
|
27605566 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a result, previous studies have not provided conclusive evidence of the prognostic value of CRP for post-infarct LVSD or HF.
|
29633232 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After multivariable adjustment for clinical variables and renal and CV biomarkers (estimated glomerular filtration rate, cystatin-C, urine albumin-to-creatinine ratio, FGF-23, high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein), low Klotho concentration remained strongly associated with increased risk of CV death or hospitalization for heart failure [adjusted hazard ratio (HR) 2.62; 95% confidence interval (CI) 1.35-5.08; P < 0.01].
|
30773798 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effect of CRP on heart failure has not been elucidated.
|
21519150 |
2011 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We collected conventional (blood pressure, cholesterol, adiposity), lifestyle, and novel (C-reactive protein, CRP) risk factors at baseline in participants from the Scottish Health Surveys (n = 5946, 44.5% men, aged 53.6 +/- 12.4 years), who were followed up over an average of 7.1 years for cardiovascular disease (CVD) events (a composite of fatal and nonfatal events incorporating acute myocardial infarction, coronary artery bypass surgery, percutaneous coronary angioplasty, stroke, heart failure).
|
19587606 |
2009 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the prospective influence of marital status, social support, depression, and C-reactive protein (CRP) on the mortality of patients with chronic HF.
|
27384414 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D supplementation in patients with CHF improved health-related quality of life and C-reactive protein levels [weighted mean difference (WMD): 6.75, 95% confidence interval (CI): 2.87 to 10.64, <i>p</i> < .001; standardised mean difference (SMD): -0.41, 95% CI: -0.71 to -0.11, <i>p</i> = .007].
|
31032644 |
2019 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After adjusting for traditional risk factors, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF (hazard ratio, 1.44; 95% confidence interval, 1.13-1.83) and mortality (hazard ratio, 1.38; 95% confidence interval, 1.11-1.63).
|
23861484 |
2013 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
High CLA% was associated with significantly reduced risk of HF after adjustment for HF risk factors and C-reactive protein (hazard ratio [95% confidence interval], 0.64 [0.43-0.96]; quartile 4 versus quartile 1).
|
29306896 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a cross-sectional analysis to investigate the relationships between inflammatory biomarkers [serum interleukin-6 (IL-6), C-reactive protein (hs-CRP) and serum amyloid A (SAA)] and median of 6 years follow-up for all-cause mortality and HF hospitalization among women with signs and symptoms of ischemia, non-obstructive CAD and preserved EF.
|
28542263 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After multivariable adjustment for baseline clinical characteristics and established biomarkers (high-sensitivity troponin I, brain-type natriuretic peptide, and high-sensitivity C-reactive protein), FGF-23 concentration in the top quartile was independently associated with an increased risk of CV death or heart failure hospitalization (adjusted hazard ratio [HR], 2.35; 95% CI, 1.82-3.02; P < .001) and its individual components.
|
29710336 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After beta-blocker treatment, hs-CRP levels are associated with functional capacity in HF patients.
|
29396658 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 2184 consecutive patients with previous MI and CRP data at baseline in the Chronic Heart Failure Registry and Analysis in the Tohoku district-2 (CHART-2) Study.
|
31358306 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, temporal changes in CRP levels were associated with cancer death in the overall cohort; HF patients with CRP ≥ 2.0 mg/L at both baseline and 1-year had significantly increased cancer death, while those with CRP ≥ 2.0 mg/L at baseline and < 2.0 mg/L at 1-year not.
|
31104823 |
2019 |